In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE Acquires Clarient To Anchor Its Molecular IVD Business

Executive Summary

GE is buying Clarient, which provides molecular cancer tests. It intends to make Clarient the cornerstone around which it builds out a molecular in vitro diagnostics business, combining Clarient with its own diagnostic imaging expertise to give it a full suite of triage and cancer diagnostic capabilities. In some ways, it could solve GE's long-standing issue of how to innovate in healthcare and move into high-value businesses without taking on the risks and timelines of pharma-style R&D.

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
Delivering Cancer Diagnostics Tools
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010
With Genoptix, Novartis Continues Its Diagnostics Build-up
Personalized Medicine In 2010: Welcome To The Establishment
Another Call for Better Risk Stratification in Cardiac Imaging
The Pace of Development of Molecular Imaging Agents
Amersham Little Help to GE Healthcare in This Down Market
GE's Personalized Play for Amersham
Amersham's Push for High-Value Diagnostics


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts